Home › Compound Library › Dasatinib (Sprycel)

Dasatinib (Sprycel)

Senolyticprescriptionoral · inferred

Potent second-generation BCR-ABL and Src-family tyrosine kinase inhibitor, FDA-approved for Philadelphia-chromosome-positive CML (100 mg QD chronic phase) and Ph+ ALL. Used off-label in longevity/senolytic protocols paired with quercetin (Mayo Clinic 'D+Q' protocol) based on preclinical studies showing selective elimination of senescent cells. Senolytic dosing is intermittent: 100 mg dasatinib + 1000 mg quercetin daily for 3 consecutive days, repeated monthly or as studied per trial. Plasma t1/2 ~3-5h; oral F ~30% (variable). CYP3A4 substrate - strong inhibitors/inducers require dose adjustment. Pharmacokinetics markedly affected by gastric pH: avoid concurrent PPIs/H2 blockers/antacids. Oncology AEs include pleural effusions, myelosuppression, QT prolongation, pulmonary arterial hypertension.

Projected serum levels — 100 mg, once daily

Dasatinib (Sprycel)
Dasatinib (Sprycel) modeled serum levels, 100 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 12.5 25 37.5 50 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 25.5 mg, trough ≈ 0.35 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Senolytic
Route modeled
Oral
Model confidence
inferred
Half-life
4 h
Common dose
100 mg
Suggested maximum
140 mg/day
Reference dose range
50–140 mg (single dose)
Suggested cadence
once daily
Validated against
100 mg oral — Cmax 0.13 mg/L at 1 h

Documented interactions

  • contraindicated
    Alfuzosin (Uroxatral) + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Alfuzosin (Uroxatral) AUC by ~5.00x

  • contraindicated
    Alprazolam (Xanax) + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Alprazolam (Xanax) AUC by ~5.00x

  • contraindicated
    Amlodipine (Norvasc) + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Amlodipine (Norvasc) AUC by ~5.00x

  • contraindicated
    Astaxanthin + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Astaxanthin AUC by ~5.00x

  • contraindicated
    Atogepant (Qulipta) + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~5.00x

  • contraindicated
    Azithromycin (Z-Pack / Zithromax) + Dasatinib (Sprycel) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Azithromycin (Z-Pack / Zithromax) AUC by ~5.00x

Serum checks 423 modeled interaction pairings for dasatinib (sprycel) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics of dasatinib Christopher LJ et al. · Clinical Cancer Research, 2008 DOI

    Phase 1/PK characterization: dasatinib F~30%, t1/2 3-5h, CYP3A4 primary metabolism, gastric pH markedly affects absorption - PPI/H2 use reduces AUC.

  2. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease Hickson LJ et al. · EBioMedicine, 2019 DOI

    First human senolytic clinical trial: 3-day intermittent D+Q (dasatinib 100 mg + quercetin 1000 mg) reduced adipose tissue senescent cell burden and SASP markers in diabetic kidney disease.

  3. Effects of Apigenin on Pharmacokinetics of Dasatinib and Probable Interaction Mechanism. Raish M, Ahmad A, Shahid M, Jardan YAB, Ahad A, Kalam MA, Ansari MA, Iqbal M, Ali N, Alkharfy KM, Al-Jenoobi FI · Molecules (Basel, Switzerland), 2023 DOI

    This citation reports an animal study involving Dasatinib (Sprycel). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.